Newsroom

Strive to Deliver Breakthroughs

  1. January 24, 2022

    Harbour BioMed Announces Dosing of First Patient in Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— January 24, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successful...

    View more
  2. January 13, 2022

    Harbour BioMed Completes the First Interim Analysis of Phase III Clinical Trial of Tanfanercept

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — January 13, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that, the Company has ...

    View more
  3. January 04, 2022

    Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — January 4, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that, its next generati...

    View more
  4. December 03, 2021

    Harbour BioMed Appoints Mr. Weihao Xu as Chief Strategy Officer

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - December 2, 2021   Harbour BioMed (“HBM”, HKEX:02142) is pleased to announce the appointment ...

    View more
  5. October 19, 2021

    Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— October 19, 2021   Harbour BioMed (“HBM”, HKEX: 02142) announced that, the clinical...

    View more
  6. September 27, 2021

    Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— September 27, 2021   Harbour BioMed (“HBM”, HKEX: 02142) announced that, the clinical tr...

    View more
  7. September 14, 2021

    Harbour BioMed Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 14, 2021   Harbour BioMed (“HBM”, HKEX: 02142) announced that the China Nation...

    View more
  8. September 13, 2021

    Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 13, 2021   Harbour BioMed (“HBM”, HKEX: 02142) announced positive results from...

    View more
  9. September 01, 2021

    Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 1, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced that the Center ...

    View more
  10. August 31, 2021

    Harbour BioMed Reports 2021 Interim Results: Product Development Breakthroughs Continue to Unlock Value of Integrated Antibody Discovery Platform

    CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - August 31, 2021   Harbour BioMed (“HBM”, or the "Company”; HKEX: 02...

    View more